SNCA and Parkinson disease: CCK analogues or GLP-1 analogues restored the disruption of intestinal tight junction, reduced colonic inflammation, inhibited colonic dopaminergic neuron reduction and the accumulation of α-synuclein oligomers in the colon of both PD mouse models.